Oral oncology最新文献

{"title":"Oral HPV incidence and risk factors for acquisition","authors":"Gypsyamber DSouza ,&nbsp;Sakshi Tewari ,&nbsp;Tanya Troy ,&nbsp;Paige Bleyer ,&nbsp;Mabel Korley ,&nbsp;Jennafer Kwait ,&nbsp;Ken Ho ,&nbsp;Maura Gillison ,&nbsp;Dorothy Wiley ,&nbsp;Jason Lazar ,&nbsp;Kathleen M. Weber ,&nbsp;Howard Strickler ,&nbsp;Cecile D Lahiri ,&nbsp;Frank Palella ,&nbsp;Linda Struijk ,&nbsp;Carole Fakhry","doi":"10.1016/j.oraloncology.2025.107249","DOIUrl":"10.1016/j.oraloncology.2025.107249","url":null,"abstract":"<div><h3>Background</h3><div>We evaluated incidence of oral HPV infection, which precedes HPV-related oropharynx cancer.</div></div><div><h3>Methods</h3><div>In this prospective multicenter cohort of participants with HIV and demographically similar participants without HIV, oral rinse and gargle samples were collected every 6–12 months and tested for 35 HPV types (anyHPV), 13 of which were oncogenic (oncHPV). Kaplan Meier and Cox regression were used for incidence curves and clustered risk factor hazard ratios. Logistic regression was used to determine relative odds of same infection at next visit.</div></div><div><h3>Results</h3><div>The 1587 participants had a median follow-up of 3.67 years, 422 had 708 incident type-specific oral HPV detected. The most common oncHPV was HPV16 [incidence rate = 7.8 per 1000 person-years (95 %CI 5.8–10.6)]. At 5 years, the cumulative incidence of anyHPV, oncHPV and HPV16 was 34.9 % (95 %CI = 31.9 %, 38.3 %), 17.1% (95 %CI = 14.8 %, 19.8 %) and 4.0 % (95 %CI = 2.9, 5.6 %), respectively. Risk of incident oral HPV infection was independently associated with a higher number of oral sex partners, current smoking, younger age, prevalent oral anyHPV, living with HIV and lower CD4 counts. Prevalent oncHPV at baseline had greater odds of being re-detected at subsequent visits than an incident oncHPV detected for the first-time at a later visit. Detection of oral HPV type at one visit was associated with highly elevated odds of detecting that same type-specific infection at the next visit (OR &gt; 100).</div></div><div><h3>Conclusion</h3><div>Cumulative incidence of oral HPV is increased among PLWH and with prevalent oral HPV, represents a mix of new and intermittently detected infections, and is higher among those with repeated detection of oral HPV.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107249"},"PeriodicalIF":4.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-year follow-up of a rare primary branchial cleft carcinoma: Case analysis and management insights","authors":"Jiayu Shen ,&nbsp;Xin Wei ,&nbsp;Zhiyan Wu ,&nbsp;Xi Li ,&nbsp;Sichen Han ,&nbsp;Xinliang Duan ,&nbsp;Yao Yuan ,&nbsp;Peng Liu ,&nbsp;Zilin Wang","doi":"10.1016/j.oraloncology.2025.107215","DOIUrl":"10.1016/j.oraloncology.2025.107215","url":null,"abstract":"<div><div>Branchial cleft cysts are congenital anomalies of development, with the second branchial cleft cyst being the most common clinically. In extremely rare cases, branchial cleft cysts can undergo malignant transformation. Herein, we present a rare case of a 65-year-old male patient who had a painless neck mass on the left side for 6 months. Routine postoperative histopathological examination of the resected mass revealed branchial cleft carcinoma. We excluded the possibility of systemic metastasis through PET-CT and subsequently performed radical neck dissection. Routine follow-up revealed no recurrence after surgery. A PubMed search of the literature over the past 10 years yielded only 11 articles related to branchial cleft carcinoma. We hope this case will remind clinicians of the insidious nature of branchial cleft carcinoma and the importance of routine histopathological examination of seemingly benign surgical lesions.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107215"},"PeriodicalIF":4.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in unmet needs after treatment for head and neck cancers – A prospective longitudinal cohort study","authors":"John Mohan Mathew ,&nbsp;Ionut Busca ,&nbsp;Zeynep Baskurt ,&nbsp;Meredith Giuliani ,&nbsp;Naa Kwarley Quartey ,&nbsp;Jennifer Jones ,&nbsp;Maureen McQuestion ,&nbsp;Janet Papadakos ,&nbsp;John Waldron ,&nbsp;Jessica Weiss ,&nbsp;Jolie Ringash","doi":"10.1016/j.oraloncology.2025.107250","DOIUrl":"10.1016/j.oraloncology.2025.107250","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to assess changes in unmet needs among patients with head and neck cancer (HNC) from pre-treatment to two years post-treatment and identify factors associated with higher levels of unmet needs.</div></div><div><h3>Materials &amp; Methods</h3><div>Patients treated for HNC at Princess Margaret Cancer Centre between June 2016 and February 2019 were recruited. Participants completed the Cancer Survivors’ Unmet Needs Measure Questionnaire (CaSUN), the Functional Assessment of Cancer Therapy − Head and Neck (FACT-HN) questionnaire, and the EuroQol EQ-5D-5L utility and Visual Analog Scale (EQ-5D-5L and VAS) pre-treatment and at 3, 6, 12, and 24-months post-treatment.</div></div><div><h3>Results</h3><div>Among 332 eligible patients approached, 197 were included. Significant reductions in number of unmet needs were observed between baseline and all follow-ups: 48 % fall at 3 months (p &lt; 0.001), 39 % at 6 (p = 0.001), 54 % at 12 (p &lt; 0.001), and 59 % at 24 months (p &lt; 0.001). Higher education (p = 0.018, RR 1.88 [95 % CI 1.1–3.1]) and lower baseline FACT-HN &amp; EQ-5D-5L VAS scores (p &lt; 0.001, RR 0.98 [95 % CI 0.96–0.99] &amp; p = 0.02, RR 0.99 [95 % CI 0.97–1 respectively]) were associated with higher unmet needs pre-treatment. Younger age (p = 0.041, RR 0.95 [95 %C I 0.9–1]) and lower baseline FACT-HN scores (p = 0.028, RR 0.97 [95 % CI 0.95–1]) were associated with higher unmet needs at 24 months.</div></div><div><h3>Conclusions</h3><div>Patients with HNC experience unmet needs, but the number declines from pre-treatment to two years post-treatment. Younger age, higher educational level, lower baseline FACT HN and EQ-5D-5L scores were associated with higher levels of unmet needs at various follow-up stages.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107250"},"PeriodicalIF":4.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma","authors":"F.Jeffrey Lorenz ,&nbsp;Michael Kharouta ,&nbsp;Sean S. Mahase ,&nbsp;Neerav Goyal ,&nbsp;Rod Rezaee ,&nbsp;Pierre Lavertu ,&nbsp;Michell Machtay ,&nbsp;Min Yao","doi":"10.1016/j.oraloncology.2025.107251","DOIUrl":"10.1016/j.oraloncology.2025.107251","url":null,"abstract":"<div><h3>Objectives</h3><div>AJCC8 introduced separate staging for HPV-associated OPSCC in 2018 to enhance prognostic discrimination. Consequently, most patients previously staged I-IVA in AJCC7 were reclassified as stage I. This study aimed to stratify AJCC8 stage I HPV-associated OPSCC patients using AJCC7 criteria to assess hazard consistency.</div></div><div><h3>Materials and Methods</h3><div>The NCDB was queried for patients diagnosed with AJCC7 T1-2 N0-2b HPV-associated OPSCC during 2010–2016 who met criteria to be restaged to AJCC8 overall stage I. Cox-proportional hazards models including AJCC7 T and N stage as covariates were generated to test for significant predictors of 5-year overall survival in patients with stage I disease according to AJCC8, which were then used to generate substages.</div></div><div><h3>Results</h3><div>A total of 5,737 patients with AJCC7 cT1-2 N0-2b HPV-associated OPSCC were identified. A multivariable Cox-proportional hazards model showed a significant association of cT2 (HR, 95 % CI, P) (1.8, 1.4–2.2, P &lt; 0.001) compared to cT1, and cN2b (1.4, 1.1–1.7, P = 0.002) compared to less than cN2b (i.e. cN0, cN1, cN2a) with 5-year OS. These results were used to generate substages of AJCC8 stage I: cT1N0-2a were designated stage IA, cT2N0-2a and cT1N2b as stage IB, and cT2N2b as stage IIA. Log-rank testing between these substages revealed significant differences between the respective survival curves at 5 years (P &lt; 0.001 for all comparisons).</div></div><div><h3>Conclusion</h3><div>Substaging of AJCC8 stage I for HPV-associated OPSCC by cT2 and cN2b (7th<!--> <!-->edition TNM stage) provided significant hazard consistency. Adoption may improve prognostic risk stratification and inform guidance in treatment decision making. Further validation of this staging is warranted.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107251"},"PeriodicalIF":4.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid volumes after intensity‐modulated radiotherapy as predictors of radiation‐induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study","authors":"Zhe Dong ,&nbsp;Gao-Yuan Wang ,&nbsp;Guan-Jie Qin,&nbsp;Dong-Yu Dai,&nbsp;Wen-Fei Li,&nbsp;Ling-Long Tang,&nbsp;Cheng Xu,&nbsp;Jun Ma","doi":"10.1016/j.oraloncology.2025.107223","DOIUrl":"10.1016/j.oraloncology.2025.107223","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to investigate the ability of thyroid volumes after intensity-modulated radiotherapy (IMRT) to predict the incidence of radiation‐induced hypothyroidism/primary hypothyroidism (HT)/(PHT) in nasopharyngeal carcinoma (NPC) patients.</div></div><div><h3>Methods and materials</h3><div>404 NPC patients were retrospectively enrolled from January 2015 to January 2019. Thyroid volumes were calculated based on magnetic resonance imaging. Volume of thyroid after IMRT within 3 months was defined as Vt-after. Least absolute shrinkage and selection operator (LASSO) regression, random forest analysis, and multivariate Cox proportional hazards were performed to identify optimal predictors of PHT. Then, these predictors were employed to construct the risk stratification using the recursive partitioning analysis (RPA).</div></div><div><h3>Results</h3><div>A smaller Vt-after was significantly associated with a higher risk of HT/PHT (hazard ratio (HR): 2.046, <em>p</em> &lt; 0.001; HR: 3.214, <em>p</em> &lt; 0.001; respectively). Vt-after and thyroid volumes at 1, 2, and 3 years after IMRT demonstrated superior predictive ability compared to the thyroid volume before IMRT for predicting PHT within the subsequent 2-year period. The combination of Vt-after and thyroid volume spared from 45 Gy (VS45), both of which were<!--> <!-->independent factors for predicting PHT, was incorporated into the RPA risk stratification called PRA-VS45. The PRA-VS45 emerged as a highly discriminative tool, with an area under the curve (AUC) of 0.716 on predicting PHT at 5 years.</div></div><div><h3>Conclusions</h3><div>This study identified thyroid volumes after IMRT as valuable parameters to predict radiation‐related PHT in NPC patients. The PRA-VS45 has the potential to be clinical applications for predicting PHT.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107223"},"PeriodicalIF":4.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of primary tumor in metastatic head and neck Carcinoma: A systematic review and Meta-Analysis","authors":"Fausto Petrelli ,&nbsp;Luigi Lorini ,&nbsp;Alberto Paderno ,&nbsp;Daniela Carioli ,&nbsp;Francesca Trevisan ,&nbsp;Vincenzo Capriotti ,&nbsp;Massimiliano Nardone ,&nbsp;Cristina Gurizzan ,&nbsp;Carlo Resteghini ,&nbsp;Paolo Bossi","doi":"10.1016/j.oraloncology.2025.107248","DOIUrl":"10.1016/j.oraloncology.2025.107248","url":null,"abstract":"<div><h3>Introduction</h3><div>The treatment of primary tumors in metastatic squamous cell carcinoma of the head and neck (HNSCC) is a complex and debated issue. This study evaluates the impact of treating primary tumors on overall survival (OS) and progression-free survival (PFS) in metastatic HNSCC through a systematic review and <em>meta</em>-analysis, with a focus on identifying potential biases and limitations in the available evidence.</div></div><div><h3>Materials and Methods</h3><div>A comprehensive literature search was conducted in PubMed, EMBASE, and The Cochrane Library for studies published up to January 2024. Studies comparing systemic therapy alone to systemic therapy combined with locoregional therapy targeting the primary tumor, with or without neck nodes, were included. Eligible studies reported OS or PFS outcomes in stage IV HNSCC or nasopharyngeal cancers. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using random-effects models to account for study heterogeneity.</div></div><div><h3>Results</h3><div>The <em>meta</em>-analysis included 48 studies comprising 33,637 patients. Treating the primary tumor significantly improved OS (HR = 0.55; 95 % CI, 0.49–0.61; P &lt; 0.01) and PFS (HR = 0.57; 95 % CI, 0.35–0.95; P = 0.03). However, significant heterogeneity was observed (I² = 86 %), reflecting variability in patient populations, treatment protocols, and study designs.</div></div><div><h3>Conclusions</h3><div>This <em>meta</em>-analysis suggests that treating the primary tumor in metastatic HNSCC may be associated with improved survival outcomes. However, these findings must be interpreted with caution due to significant limitations, including high heterogeneity, potential biases, and the predominance of retrospective studies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107248"},"PeriodicalIF":4.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction chemotherapy and concurrent chemoradiotherapy with cisplatin for T4 nasoethmoidal squamous cell carcinoma: The value of paclitaxel, carboplatin and cetuximab (PCE)","authors":"Nobukazu Tanaka ,&nbsp;Tomohiro Enokida ,&nbsp;Susumu Okano ,&nbsp;Takao Fujisawa ,&nbsp;Hideki Tanaka ,&nbsp;Ryutaro Onaga ,&nbsp;Yuta Hoshi ,&nbsp;Takuma Kishida ,&nbsp;Akihisa Wada ,&nbsp;Masanobu Sato ,&nbsp;Naohiro Takeshita ,&nbsp;Takeshi Fujisawa ,&nbsp;Atsushi Motegi ,&nbsp;Sadamoto Zenda ,&nbsp;Tetsuo Akimoto ,&nbsp;Makoto Tahara","doi":"10.1016/j.oraloncology.2025.107235","DOIUrl":"10.1016/j.oraloncology.2025.107235","url":null,"abstract":"<div><h3>Background</h3><div>Locally advanced nasoethmoidal squamous cell carcinoma (SCC) is rare and often unsuitable for surgical resection. Data on the potential clinical benefits of combining induction chemotherapy (IC) and sequential definitive chemoradiotherapy for this condition is limited.</div></div><div><h3>Methods</h3><div>We retrospectively investigated T4 nasoethmoidal SCC patients who underwent proton or photon chemoradiotherapy with curative intent at the National Cancer Center Hospital East between April 2014 and May 2022. Patients were categorized into three groups based on IC regimen: no IC (No-IC), paclitaxel plus carboplatin plus cetuximab (IC-PCE), and docetaxel plus cisplatin plus S-1 (IC-TPS).</div></div><div><h3>Results</h3><div>Twenty-five patients were analyzed (No IC, 9; IC-PCE, 10; and IC-TPS, 6). The IC-PCE group had the highest ratio of Stage IVB to IVA patients. IC-PCE and IC-TPS yielded objective responses in eight (80 %) and two (33 %) patients, respectively. All subjects completed radiotherapy, with the median relative to dose intensity of concurrent cisplatin reaching 100 % in all groups. Complete responses were observed in 22 patients. Three patients in the No IC or IC-TPS group showed a partial response after the completion of planned treatment. On a median follow-up of 42 months, the 3-year recurrence-free survival (RFS) rate was 90.0 % in the IC-PCE group and 33.3 % in the remaining groups. Of note, the IC-PCE group had significantly better RFS (log-rank p-value; 0.023) despite no differences in overall survival, time-to-locoregional progression, or time-to-distant metastasis.</div></div><div><h3>Conclusion</h3><div>Sequential IC-PCE followed by concurrent chemoradiotherapy with cisplatin appears promising as an effective therapeutic strategy for T4 nasoethmoidal SCC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107235"},"PeriodicalIF":4.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Hyalinizing parotid adenoid cystic carcinoma with dystrophic calcification masquerading as a thyroid-like carcinoma”","authors":"Fumio Ide,&nbsp;Shinnichi Sakamoto,&nbsp;Michiko Nishimura,&nbsp;Yuji Miyazaki,&nbsp;Kentaro Kikuchi","doi":"10.1016/j.oraloncology.2025.107233","DOIUrl":"10.1016/j.oraloncology.2025.107233","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107233"},"PeriodicalIF":4.0,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA","authors":"Fabian Rosing ,&nbsp;Michaela Plath ,&nbsp;Tanja Proctor ,&nbsp;Daniela Höfler ,&nbsp;Yvonne Alt ,&nbsp;Carlota Lucena-Porcel ,&nbsp;Tim Waterboer ,&nbsp;Jochen Hess ,&nbsp;Karim Plath ,&nbsp;Lea Schroeder","doi":"10.1016/j.oraloncology.2025.107225","DOIUrl":"10.1016/j.oraloncology.2025.107225","url":null,"abstract":"<div><h3>Introduction</h3><div>The incidence rate of human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC) is increasing. Despite good prognosis, recurrence can decrease health-related quality of life and increase mortality, so post-treatment monitoring is important for patient outcomes. One potential biomarker for post-treatment monitoring is HPV cell-free DNA (cfDNA) from blood plasma.</div></div><div><h3>Methods</h3><div>Plasma samples at start of treatment and during follow-up from 27 OPSCC patients were analyzed for cfDNA of six high-risk HPV types using a multiplex digital PCR assay. Presence of HPV cfDNA was compared to HPV tumor status determined by p16^INK4a immunohistochemistry, HPV DNA, HPV RNA and HPV16 E6 serology.</div></div><div><h3>Results</h3><div>At start of treatment, sensitivity of HPV cfDNA detection in HPV-driven OPSCC cases was 89 % (17/19), while specificity was 100 % among 39 plasma samples from 8 HPV-negative OPSCC cases. A median of 4 follow-up plasma samples per patient over a mean time of 11 months were available. Positive and negative predictive values during follow-up were assessed on a per-test-basis. HPV cfDNA testing after completion of therapy had a positive predictive value of 100 % for HPV-OPSCC recurrence within one year, and a negative predictive value of 98 %. In cases of recurrent HPV-driven OPSCC, HPV cfDNA was detectable between 3 and 6.8 months before detection of recurrence by routine follow-up examination methods.</div></div><div><h3>Conclusion</h3><div>Post-treatment monitoring for early detection of recurrence could be aided by testing for HPV cfDNA in HPV-driven OPSCC patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107225"},"PeriodicalIF":4.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing knowledge gaps in HPV-related oropharyngeal cancer prevention: A call for action","authors":"Sarah M. Dermody ,&nbsp;Heather Walline ,&nbsp;Chandan Bhambhani ,&nbsp;Muneesh Tewari ,&nbsp;Paul L. Swiecicki ,&nbsp;Michelle Mierzwa ,&nbsp;Molly E. Heft Neal ,&nbsp;Matthew E. Spector ,&nbsp;J. Chad Brenner","doi":"10.1016/j.oraloncology.2025.107234","DOIUrl":"10.1016/j.oraloncology.2025.107234","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"163 ","pages":"Article 107234"},"PeriodicalIF":4.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143551932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}